Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 12, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 875,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,229.98 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,210,454,305 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 875,000 repurchased shares. Consequently, the total number of shares in issue remains 5,210,454,305, while the Treasury holding stands at 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,210,454,305) for calculating disclosure thresholds under FSA rules.
- Confirm the Treasury share count (474,194,158) and its percentage of total voting rights (9.10%).
- Note that this transaction was a cancellation of shares, not a retention for future issuance.
- Recognize that this filing does not contain operational or financial performance data for the period.